CORRECTION to 27 June 2024 Tender Notification - 12 July 2024
Pharmac | Te Pātaka Whaioranga is pleased to provide the latest tender results.
- Download the tender notification [PDF 272 KB]
Correction to 27 June 2024 Tender Notification
- Correction of packet type for zopiclone 7.5 mg.
- Removal of price change footnote for zopiclone 7.5 mg.
- Correction to brand name for azacytidine inj 1 mg for ECP (Baxter).
- Note of Section B price change for midazolam inj 1 mg per ml, 5 ml ampoule and inj 5 mg per ml, 3 ml ampoule.
Corrections in bold and strikethrough below.
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2023/24 Invitation to Tender dated 31 October 2023.
Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on the 12th of July 2024 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website.
Suppliers are required to ensure that a Pharmacode(external link) has been obtained from the Pharmacy Guild of New Zealand and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.
2023/24 Tender – Principal Supply Status applies until 30 June 2027
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
|
Bosentan |
Tab 62.5 mg |
$119.85 |
$100.00 |
Bosentan Dr Reddy's (Dr Reddy's) |
1 August 2024 |
1 January 2025 |
|
Bosentan |
Tab 125 mg |
$119.85 |
$100.00 |
Bosentan Dr Reddy's (Dr Reddy's) |
1 August 2024 |
1 January 2025 |
|
Midodrine |
Tab 5 mg; 100 tablet blister pack |
$59.98 |
$58.88 |
Midodrine Medsurge (Medsurge) |
1 September 2024 |
1 February 2025 |
|
Zopiclone1 |
Tab 7.5 mg; 500 tablet |
$10.80 |
$21.85 |
Zopiclone Actavis (Teva) |
1 September 2024 |
1 February 2025 |
|
|
||||||
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|
Amoxicillin with clavulanic acid |
Grans for oral liquid amoxicillin 50 mg with clavulanic acid 12.5 mg per ml; 100 ml bottle OP |
$2.20 |
$5.61 |
Amoxiclav Devatis Forte (Devatis) |
1 November 2024 |
1 June 2025 |
Curam (Sandoz) |
|
Flucloxacillin |
Cap 250 mg; 250 capsule bottle pack |
$15.79 |
$22.58 |
Staphlex (Viatris) |
1 March 2025 |
1 August 2025 |
Flucloxacillin-AFT (AFT) |
|
Flucloxacillin |
Cap 500 mg; 500 capsule bottle pack |
$52.99 |
$72.71 |
Staphlex (Viatris) |
1 March 2025 |
1 August 2025 |
Flucloxacillin-AFT (AFT) |
|
Hyoscine butylbromide |
Tab 10 mg; 20 tablet blister pack |
$6.35 (per 100) |
$2.25 |
Adiramedica Hyoscine Butylbromide (Adiramedica) |
1 November 2024 |
1 April 2025 |
Buscopan (Sanofi) |
|
Ibuprofen |
Tab long-acting 800 mg; 30 tablet blister pack |
$3.05 |
$3.65 |
Ibuprofen SR BNM (Boucher) |
1 November 2024 |
1 April 2025 |
Brufen SR (Viatris) |
|
Isoniazid |
Tab 100 mg; 100 tablet blister pack |
$23.00 |
$327.41 |
Noumed Isoniazid (Noumed) |
1 December 2024 |
1 May 2025 |
PSM (PSM) |
|
Midodrine |
Tab 2.5 mg; 100 tablet blister pack |
$38.68 |
$36.68 |
Midodrine Medsurge (Medsurge) |
1 September 2024 |
1 February 2025 |
MAR-Midodrine S29 (Marcan) |
|
Naphazoline hydrochloride |
Eye drops 0.1%; 15 ml dropper bottle OP |
$4.15 |
$5.65 |
Albalon (Abbvie) |
1 August 2024 |
1 January 2025 |
Naphcon Forte (Alcon) |
|
Oil in water emulsion |
Emulsion crm; 500 g tub |
$2.04 |
$2.10 |
Fatty Emulsion Cream (Evara) |
1 November 2024 |
1 April 2025 |
Fatty Cream AFT (AFT) |
|
Solifenacin succinate |
Tab 5 mg; 30 tablet blister pack |
$2.05 |
$1.95 |
Solifenacin succinate Max Health (Max Health) |
1 January 2025 |
1 June 2025 |
Solifenacin Viatris (Viatris) |
|
Solifenacin succinate |
Tab 10 mg; 30 tablet blister pack |
$3.72 |
$3.53 |
Solifenacin succinate Max Health (Max Health) |
1 January 2025 |
1 June 2025 |
Solifenacin Viatris (Viatris) |
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV Limit |
Listing date |
Principal Supply date |
|
Azacitidine2 |
Inj 100 mg vial; 1 injection pack |
$75.06 |
$50.00 |
Azacitidine Dr Reddy’s (Dr Reddy’s) |
5% |
1 October 2024 |
1 March 2025 |
|
Bosentan |
Tab 62.5 mg; 60 tablet blister pack |
$119.85 |
$100.00 |
Bosentan Dr Reddy's (Dr Reddy's) |
5% |
1 August 2024 |
1 January 2025 |
|
Bosentan |
Tab 125 mg; 60 tablet blister pack |
$119.85 |
$100.00 |
Bosentan Dr Reddy's (Dr Reddy's) |
5% |
1 August 2024 |
1 January 2025 |
|
Chlorhexidine gluconate |
Mouthwash 0.2%; 200 ml bottle |
N/A* |
$3.99 |
healthE (Jaychem) |
5% |
1 August 2024 |
1 January 2025 |
|
Midodrine |
Tab 2.5 mg; 100 tablet blister pack |
$38.68 |
$36.68 |
Midodrine Medsurge (Medsurge) |
5% |
1 September 2024 |
1 February 2025 |
|
Midodrine |
Tab 5 mg; 100 tablet blister pack |
$59.98 |
$58.88 |
Midodrine Medsurge (Medsurge) |
5% |
1 September 2024 |
1 February 2025 |
|
Zopiclone3 |
Tab 7.5 mg; 500 tablet |
N/A* |
$21.85 |
Zopiclone Actavis (Teva) |
5% |
1 September 2024 |
1 February 2025 |
|
2The price and subsidy of azacitidine (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be listed at the above prices from 1 October 2024. The subsidy of azacitidine inj 1 mg for ECP (
*This product is listed in Section H of the Pharmaceutical Schedule as “Any Brand”. |
|||||||
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV Limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|
Amoxicillin with clavulanic acid |
Grans for oral liquid amoxicillin 50 mg with clavulanic acid 12.5 mg per ml; 100 ml bottle |
$2.20 |
$5.61 |
Amoxiclav Devatis Forte (Devatis) |
5% |
1 November 2024 |
1 June 2025 |
Curam (Sandoz) |
|
Amoxicillin with clavulanic acid |
Inj 500 mg with clavulanic acid 100 mg vial; 10 vial pack |
$17.50 |
$22.48 |
Synermox (Douglas) |
5% |
1 February 2025 |
1 September 2025 |
Amoxiclav Multichem (Multichem) |
|
Amoxicillin with clavulanic acid |
Inj 1,000 mg with clavulanic acid 200 mg vial; 10 vial pack |
$26.90 |
$29.61 |
Synermox (Douglas) |
5% |
1 February 2025 |
1 September 2025 |
Amoxiclav Multichem (Multichem) |
|
Flucloxacillin |
Cap 250 mg; 250 capsule bottle pack |
$15.79 |
$22.58 |
Staphlex (Viatris) |
5% |
1 March 2025 |
1 August 2025 |
Flucloxacillin-AFT (AFT) |
|
Flucloxacillin |
Cap 500 mg; 500 capsule bottle pack |
$52.99 |
$72.71 |
Staphlex (Viatris) |
5% |
1 March 2025 |
1 August 2025 |
Flucloxacillin-AFT (AFT) |
|
Hyoscine butylbromide |
Tab 10 mg; 20 tablet blister pack |
$6.35 (per 100) |
$2.25 |
Adiramedica Hyoscine Butylbromide (Adiramedica) |
5% |
1 November 2024 |
1 April 2025 |
Buscopan (Sanofi) |
|
Ibuprofen |
Tab long-acting 800 mg; 30 tablet blister pack |
$3.05 |
$3.65 |
Ibuprofen SR BNM (Boucher) |
5% |
1 November 2024 |
1 April 2025 |
Brufen SR (Viatris) |
|
Isoniazid |
Tab 100 mg; 100 tablet blister pack |
$23.00 |
$327.41 |
Noumed Isoniazid (Noumed) |
5% |
1 December 2024 |
1 May 2025 |
PSM (PSM) |
|
Midazolam3 |
Inj 1 mg per ml, 5 ml ampoule; 10 glass ampoule pack |
$3.95 |
$7.80 |
Midazolam-Baxter (Baxter) |
5% |
1 August 2024 |
1 January 2025 |
Mylan Midazolam (Viatris) Midazolam Viatris (Viatris) |
|
Midazolam3 |
Inj 5 mg per ml, 3 ml ampoule; 5 glass ampoule pack |
$3.52 |
$4.75 |
Midazolam-Baxter (Baxter) |
5% |
1 August 2024 |
1 January 2025 |
Mylan Midazolam (Viatris) Midazolam Viatris (Viatris) |
|
Naphazoline hydrochloride |
Eye drops 0.1%; 15 ml dropper bottle |
$4.15 |
$5.65 |
Albalon (Abbvie) |
5% |
1 August 2024 |
1 January 2025 |
Naphcon Forte (Alcon) |
|
Oil in water emulsion |
Emulsion crm; 100 g tube |
$1.59 |
$1.43 |
Fatty Emulsion Cream (Evara) |
5% |
1 November 2024 |
1 April 2025 |
healthE Fatty Cream (Jaychem) |
|
Oil in water emulsion |
Emulsion crm; 500 g tub |
$2.04 |
$2.10 |
Fatty Emulsion Cream (Evara) |
5% |
1 November 2024 |
1 April 2025 |
Fatty Cream AFT (AFT) |
|
Solifenacin succinate |
Tab 5 mg; 30 tablet blister pack |
$2.05 |
$1.95 |
Solifenacin succinate Max Health (Max Health) |
5% |
1 January 2025 |
1 June 2025 |
Solifenacin Viatris (Viatris) |
|
Solifenacin succinate |
Tab 10 mg; 30 tablet blister pack |
$3.72 |
$3.53 |
Solifenacin succinate Max Health (Max Health) |
5% |
1 January 2025 |
1 June 2025 |
Solifenacin Viatris (Viatris) |
| 3The price and subsidy of Midazolam-Baxter (Baxter) in Section B of the Pharmaceutical Schedule will also be listed at the above prices from 1 August 2024 | ||||||||
Tender declines – Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2021/22 Invitation to Tender, dated 1 November 2021.
|
Chemical Name |
Line Item |
|
Trientine |
Tab 150 mg |
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2023/24 Invitation to Tender, dated 31 October 2023.
|
Chemical Name |
Line Item |
|
Azacitidine (widened access) |
Inj 100 mg |
|
Ibuprofen |
Inj 5 mg per ml, 2 ml |
|
Noradrenaline |
Inj 0.06 mg per ml, 50 ml |
|
Noradrenaline |
Inj 0.1 mg per ml, 50 ml |
|
Oestradiol valerate |
Tab 2 mg |
|
Omeprazole |
Oral Suspension |
|
Paracetamol with Ibuprofen |
Inj 1000 mg with ibuprofen 300 mg |
|
Prasugrel |
Tab 5 mg |
|
Prasugrel |
Tab 10 mg |
|
Terlipressin |
Inj 0.2 mg per ml, 10 ml |
|
Terlipressin |
Inj 1 mg per 8.5 ml |
|
Varenicline tartrate |
Tab 0.5 mg x 11 and 1 mg x 42 |
|
Varenicline tatrate |
Tab 1 mg |
|
Zopiclone |
Tab 3.75 mg |
For products included in the 2022/23 and 2023/24 Invitation to Tender where no announcement has yet been made, a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.